ABMC
American Bio Medica Corporation [ABMC] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ABMC Stock Summary
In the News
ABMC Reports Second Quarter 2021 Results
KINDERHOOK, NY / ACCESSWIRE / August 18, 2021 / American Bio Medica Corporation (OTCQB:ABMC) today announced financial results for the three and six months ended June 30, 2021. Chief Executive Officer Melissa A.
ABMC Financial details
ABMC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.13 | 0.11 | 0.12 | 0.05 | 0.02 | |
| Net income per share | -0.03 | -0.02 | -0.02 | -0.01 | -0.03 | |
| Operating cash flow per share | -0.01 | 0 | -0.01 | -0.02 | -0.02 | |
| Free cash flow per share | -0.01 | 0 | -0.01 | -0.02 | -0.02 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | -0.02 | -0.04 | -0.02 | -0.05 | |
| Tangible book value per share | -0.01 | -0.03 | -0.04 | -0.02 | -0.05 | |
| Share holders equity per share | 0 | -0.02 | -0.04 | -0.02 | -0.05 | |
| Interest debt per share | 0.06 | 0.06 | 0.06 | 0.04 | 0.05 | |
| Market cap | 2.07M | 2.28M | 4.62M | 1.6M | 264.1K | |
| Enterprise value | 3.49M | 3.84M | 6.4M | 3.07M | 2.47M | |
| P/E ratio | -2.01 | -3.34 | -5.81 | -3.46 | -0.19 | |
| Price to sales ratio | 0.53 | 0.62 | 1.11 | 0.72 | 0.29 | |
| POCF ratio | -9.41 | 39.26 | -9.57 | -2.38 | -0.34 | |
| PFCF ratio | -8.56 | 39.26 | -9.49 | -2.38 | -0.34 | |
| P/B Ratio | -14.18 | -2.88 | -3.68 | -1.7 | -0.11 | |
| PTB ratio | -14.18 | -2.88 | -3.68 | -1.7 | -0.11 | |
| EV to sales | 0.9 | 1.05 | 1.54 | 1.38 | 2.71 | |
| Enterprise value over EBITDA | -4.57 | -6.48 | -10.31 | -7.07 | -2.12 | |
| EV to operating cash flow | -15.84 | 66.24 | -13.26 | -4.56 | -3.22 | |
| EV to free cash flow | -14.4 | 66.24 | -13.15 | -4.56 | -3.22 | |
| Earnings yield | -0.5 | -0.3 | -0.17 | -0.29 | -5.34 | |
| Free cash flow yield | -0.12 | 0.03 | -0.11 | -0.42 | -2.91 | |
| Debt to equity | -10.47 | -1.99 | -1.5 | -1.67 | -0.96 | |
| Debt to assets | 0.62 | 0.76 | 0.98 | 0.84 | 1.77 | |
| Net debt to EBITDA | -1.86 | -2.64 | -2.87 | -3.38 | -1.9 | |
| Current ratio | 0.88 | 0.73 | 0.58 | 0.47 | 0.21 | |
| Interest coverage | -2.68 | -2.24 | -3.55 | -6.08 | -6.4 | |
| Income quality | 0.21 | -0.09 | 0.61 | 1.45 | 0.54 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.36 | 0.34 | 0.31 | 0.6 | 1 | |
| Research and developement to revenue | 0.02 | 0.02 | 0.02 | 0.04 | 0.09 | |
| Intangibles to total assets | 0.05 | 0.06 | 0.06 | 0 | 0 | |
| Capex to operating cash flow | 0.1 | 0 | 0.01 | 0 | 0 | |
| Capex to revenue | -0.01 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.27 | 0 | -0.05 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.02 | |
| Graham number | 0.06 | 0.11 | 0.13 | 0.07 | 0.18 | |
| ROIC | -0.55 | -0.66 | -0.89 | -1.75 | 13.97 | |
| Return on tangible assets | -0.44 | -0.35 | -0.44 | -0.25 | -1.11 | |
| Graham Net | -0.06 | -0.07 | -0.07 | -0.05 | -0.07 | |
| Working capital | -212K | -460K | -841K | -1.48M | -2.83M | |
| Tangible asset value | -269K | -906K | -1.36M | -944K | -2.34M | |
| Net current asset value | -1.01M | -1.64M | -2M | -1.49M | -2.84M | |
| Invested capital | -10.47 | -1.99 | -1.5 | -1.67 | -0.96 | |
| Average receivables | 400K | 411K | 388.5K | 565K | 503.5K | |
| Average payables | 372K | 505.5K | 614.5K | 629.5K | 721K | |
| Average inventory | 1.25M | 914.5K | 673K | 489.5K | 411K | |
| Days sales outstanding | 42.61 | 36.95 | 35.82 | 118.98 | 113.54 | |
| Days payables outstanding | 50.71 | 96.31 | 72.4 | 149.06 | 250.81 | |
| Days of inventory on hand | 143.94 | 119.65 | 67.25 | 96.82 | 125.08 | |
| Receivables turnover | 8.57 | 9.88 | 10.19 | 3.07 | 3.21 | |
| Payables turnover | 7.2 | 3.79 | 5.04 | 2.45 | 1.46 | |
| Inventory turnover | 2.54 | 3.05 | 5.43 | 3.77 | 2.92 | |
| ROE | 7.04 | 0.86 | 0.63 | 0.49 | 0.6 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.01 | -0.01 | 0.08 | 0 | 0 | |
| Operating cash flow per share | 0 | -0.01 | -0.01 | 0 | 0 | |
| Free cash flow per share | 0 | -0.01 | -0.01 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | -0.04 | -0.05 | -0.01 | 0 | 0 | |
| Tangible book value per share | -0.04 | -0.05 | -0.01 | 0 | 0 | |
| Share holders equity per share | -0.04 | -0.05 | -0.01 | 0 | 0 | |
| Interest debt per share | 0.03 | 0.05 | 0 | 0 | 0 | |
| Market cap | 913.87K | 264.54K | 847.74K | 0 | 0 | |
| Enterprise value | 2.52M | 2.47M | 954.74K | 0 | 0 | |
| P/E ratio | -0.62 | -0.21 | 0.05 | 0 | 0 | |
| Price to sales ratio | 4.37 | 1.58 | 5.17 | 0 | 0 | |
| POCF ratio | -12.18 | -0.43 | -2.34 | 0 | 0 | |
| PFCF ratio | -12.18 | -0.43 | -2.34 | 0 | 0 | |
| P/B Ratio | -0.45 | -0.11 | -1.85 | 0 | 0 | |
| PTB ratio | -0.45 | -0.11 | -1.85 | 0 | 0 | |
| EV to sales | 12.05 | 14.79 | 5.82 | 0 | 0 | |
| Enterprise value over EBITDA | -10.12 | -9.39 | -0.85 | 0 | 0 | |
| EV to operating cash flow | -33.58 | -4.04 | -2.63 | 0 | 0 | |
| EV to free cash flow | -33.58 | -4.04 | -2.63 | 0 | 0 | |
| Earnings yield | -0.4 | -1.21 | 4.66 | 0 | 0 | |
| Free cash flow yield | -0.08 | -2.31 | -0.43 | 0 | 0 | |
| Debt to equity | -0.8 | -0.96 | -0.38 | 0 | 0 | |
| Debt to assets | 1.37 | 1.77 | 0.27 | 0 | 0 | |
| Net debt to EBITDA | -6.45 | -8.39 | -0.1 | 0 | 0 | |
| Current ratio | 0.21 | 0.21 | 0.59 | 0 | 0 | |
| Interest coverage | -4.94 | -30.29 | -10.1 | 0 | 0 | |
| Income quality | 0.24 | 1.93 | -0.19 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.98 | 1.21 | 1.45 | 0 | 0 | |
| Research and developement to revenue | 0.11 | 0.13 | 0.17 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.08 | 0.09 | 0.13 | 0 | 0 | |
| ROIC | 0.79 | 14.04 | 1.57 | 0 | 0 | |
| Return on tangible assets | -0.31 | -0.25 | 6 | 0 | 0 | |
| Graham Net | -0.06 | -0.07 | -0.02 | 0 | 0 | |
| Working capital | -2.52M | -2.83M | -458K | 0 | 0 | |
| Tangible asset value | -2.02M | -2.34M | -458K | 0 | 0 | |
| Net current asset value | -2.53M | -2.84M | -458K | 0 | 0 | |
| Invested capital | -0.8 | -0.96 | -0.38 | 0 | 0 | |
| Average receivables | 263K | 262.5K | 287.5K | 145.5K | 0 | |
| Average payables | 917.5K | 855K | 666K | 286K | 0 | |
| Average inventory | 390.5K | 379.5K | 238.5K | 49K | 0 | |
| Days sales outstanding | 103.78 | 153.05 | 159.7 | 0 | 0 | |
| Days payables outstanding | 392.2 | 222.8 | 572 | 0 | 0 | |
| Days of inventory on hand | 156.88 | 111.11 | 98 | 0 | 0 | |
| Receivables turnover | 0.87 | 0.59 | 0.56 | 0 | 0 | |
| Payables turnover | 0.23 | 0.4 | 0.16 | 0 | 0 | |
| Inventory turnover | 0.57 | 0.81 | 0.92 | 0 | 0 | |
| ROE | 0.18 | 0.14 | -8.63 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ABMC Frequently Asked Questions
What is American Bio Medica Corporation stock symbol ?
American Bio Medica Corporation is a US stock , located in Kinderhook of Ny and trading under the symbol ABMC
What is American Bio Medica Corporation stock quote today ?
American Bio Medica Corporation stock price is $0.0003 today.
Is American Bio Medica Corporation stock public?
Yes, American Bio Medica Corporation is a publicly traded company.
Company Profile
- Volume Average 21.45K
- Market Capitalization 14.43K
- Employee 16
- CEO Ms. Jean Neff
- Headquarters Kinderhook,NY,US
- IPO Date 1997-12-24
-
Website
https://www.abmc.com 
American Bio Medica Corporation engages in manufacture and sale of lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 1 to 10 drugs; and Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 16 drugs. The company also offers OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse, as well as products to detect certain infectious diseases. Further, it provides strip contract manufacturing, assembly, and packaging services to non-affiliated diagnostic companies. The company serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets. It operates in the United States, Europe, the Asia Pacific, and South America. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was incorporated in 1986 and is based in Kinderhook, New York.
